help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermus, R. M.
Right arrow Articles by Kloppenborg, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermus, R. M.
Right arrow Articles by Kloppenborg, P. W.

Endocrinology, Vol 131, 2139-2146, Copyright © 1992 by Endocrine Society


ARTICLES

Continuous infusion of interleukin-1 beta induces a nonthyroidal illness syndrome in the rat

RM Hermus, CG Sweep, MJ van der Meer, HA Ross, AG Smals, TJ Benraad and PW Kloppenborg
Department of Medicine, Sint Radboud Hospital, University of Nijmegen, The Netherlands.

We studied the effects of continuous administration of recombinant human interleukin-1 beta (IL-1) on pituitary-thyroid function. Rats were equipped with minipumps loaded with either IL-1 (delivery rate, 0.5, 2.0, or 4.0 micrograms/day, ip, for 1 week) or saline. Infusion of 2.0 and 4.0 micrograms IL-1/day caused a significant decrease in plasma free T4 levels during the first 2-4 days, whereas plasma total T4 levels and T4 binding were significantly lowered throughout the week of the study. The infusion of 0.5 micrograms IL-1/day did not significantly change plasma TSH or total and free T4 levels. During the infusion of 2.0 micrograms IL-1/day, the decrease in plasma free T4 levels was paralleled by a significant decline in plasma TSH values and an impaired TSH responsiveness to TRH administration on the second day of infusion. IL-1 (2.0 micrograms/day) treatment significantly lowered plasma levels of T4-binding prealbumin, whereas it did not influence the plasma T3/T4 ratio or hepatic 5'-deiodinase activity. Plasma rT3 levels remained undetectable in both control and IL-1-treated rats. Chronic infusion of rats with 4.0 micrograms IL-1/day induced prolonged fever, whereas at the lower doses of IL-1, temperatures were elevated only on the first 2 days. IL-1 at doses of 2.0 and 4.0 micrograms/day induced a transient decrease in food intake and a suppression of body weight gain. Restriction of food consumption to the level observed in the 2.0 micrograms IL-1 experiment caused small decreases in T3, total and free T4, and TSH levels compared to those in ad libitum fed rats, but had no effects on T4 binding. We conclude that 1) continuous infusion of rats with 2.0 and 4.0 micrograms IL-1/day induces changes in thyroid economy commonly seen during infectious diseases and other systemic illnesses in rats [decreased plasma levels of TSH, T3, and (free) T4; diminished T4 binding; and decreased plasma T4-binding prealbumin levels], 2) the decrease in food intake during IL-1 treatment cannot completely explain the observed changes in thyroid hormone and TSH levels; and 3) it is highly unlikely that the decrease in thyroid hormone binding during chronic IL-1 infusion is caused by decreased food intake. Further studies are needed to clarify whether the observed alterations in thyroid economy during IL-1 infusion reflect direct effects of IL-1 per se or indirect effects caused by the mild illness induced by the cytokine.


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. D. van Anholt, T. Spanings, W. Koven, and S. E. W. Bonga
Effects of acetylsalicylic acid treatment on thyroid hormones, prolactins, and the stress response of tilapia (Oreochromis mossambicus)
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1098 - R1106.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. D. Mainwaring, E. Capparelli, K. Schell, M. Acosta, and J. C. Nelson
Pharmacokinetic Evaluation of Triiodothyronine Supplementation in Children After Modified Fontan Procedure
Circulation, March 28, 2000; 101(12): 1423 - 1429.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. De Groot
Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 151 - 164.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
R. D. Mainwaring, J. J. Lamberti, and T. E. Hugli
Complement Activation and Cytokine Generation After Modified Fontan Procedure
Ann. Thorac. Surg., June 1, 1998; 65(6): 1715 - 1720.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Suzuki, P. Pilowsky, J. Minson, L. Arnolda, I. Llewellyn-Smith, and J. Chalmers
Antisense to Thyrotropin Releasing Hormone Receptor Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats
Circ. Res., October 1, 1995; 77(4): 679 - 683.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society